Posts by: Alice Melão

News

The first patient has been treated in a Phase 1 clinical trial evaluating a combination of INCB01158 (aka CB-1158) plus Keytruda (pembrolizumab) in patients with advanced solid tumors. The trial, ... Read more

October 26, 2017

Non-small Cell Lung Cancer Patients Survive Two Years After Receiving Tecentriq, Trial Shows

News

Patients with advanced non-small cell lung cancer whose first therapy was Genentech‘s Tecentriq (atezolizumab) survived a median of two years after treatment, according to long-term results of a Phase 2 clinical trial. The benefits ... Read more

October 25, 2017October 30, 2017

Potential Glioblastoma Therapy Safe to Deliver, Medicenna’s Interim Phase 2 Data Shows

News

A planned safety review of a Phase 2 trial evaluating MDNA55 to treat glioblastoma has shown that the drug, developed by Medicenna Therapeutics is safe to deliver precisely into a patient’s tumor, avoiding ... Read more

October 24, 2017

Last Participants Enrolled in Phase 2/3 Trial of NBTXR3 for Soft Tissue Sarcoma

News

Nanobiotix has completed patient enrollment in its Phase 2/3 trial (Act.In.Sarc), which is evaluating the safety and effectiveness of NBTXR3 in soft tissue sarcoma patients. The last patients are expected to initiate ... Read more

September 29, 2017September 29, 2017

IMO-2125, Yervoy Combo Shows Promise in Preclinical Data and Phase 1 Studies

News

Combining IMO-2125 and an anti-CTLA-4 antibody induces long-term systemic anti-cancer immune responses in mice that outperform those seen with either of the treatments alone, according to recent preclinical results presented at ... Read more

September 26, 2017September 26, 2017

FDA Grants Accelerated Approval to Keytruda for Gastric Cancer

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Merck’s Keytruda (pembrolizumab) for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The approval ... Read more

September 26, 2017

FDA OKs Opdivo as Liver Cancer Therapy for Patients Who Did Not Respond to Nexavar

News

Patients with the most common liver cancer subtype, hepatocellular carcinoma (HCC), who have not responded to Nexavar (sorafenib), now can be treated with Opdivo (nivolumab), following an accelerated approval granted by the ... Read more

September 18, 2017

X4P-001 and Inlyta Combo Shows Promise Against Kidney Cancer, Trial Indicates

News

A combination of X4P-001 and Inlyta (axitinib) has shown signs of activity against clear cell renal cell carcinoma (ccRCC) in a Phase 1/2 clinical trial. X4 Pharmaceuticals, which developed X4P-001, presented the findings in a poster session at the ... Read more

September 14, 2017September 14, 2017

Rocapuldencel-T Improves Survival in Renal Cell Carcinoma Patients, Phase 3 Trial Suggests

News

Adding Rocapuldencel-T (AGS-003) to standard-of-care treatment may lengthen the survival of patients with newly diagnosed metastatic renal cell carcinoma, according to data presented at the European Society for Medical Oncology (ESMO) 2017 ... Read more

September 8, 2017September 8, 2017

Opdivo, Yervoy Combo Lengthens Survival Time in Renal Cell Carcinoma Patients, Supporting Early Trial End

News

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) was more effective in prolonging the lives of newly diagnosed metastatic renal cell carcinoma patients than the current standard of care, Sutent (sunitinib), new data from ... Read more